for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sun Pharmaceutical Industries Limited

SUN.NS

Latest Trade

611.20INR

Change

-7.75(-1.25%)

Volume

6,127,488

Today's Range

606.90

 - 

619.45

52 Week Range

312.00

 - 

654.40

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
618.95
Open
619.45
Volume
6,127,488
3M AVG Volume
180.27
Today's High
619.45
Today's Low
606.90
52 Week High
654.40
52 Week Low
312.00
Shares Out (MIL)
2,399.33
Market Cap (MIL)
1,466,474.00
Forward P/E
24.56
Dividend (Yield %)
0.98

Next Event

Sun Pharmaceutical Industries Ltd Court Meeting

Latest Developments

更多

Sun Pharma To Buy Stake In WRS Bioproducts For A$2 Mln

Sun Pharma Says Global Specialty Sales Have Crossed Pre-COVID Levels In Qtr

India's Sun Pharma Dec-Qtr Consol Net PAT Jumps

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New Zealand and other markets. The Company offers its products to therapy areas, such as cardiology, neuro-psychiatry, gastroenterology, anti-infective, diabetology and dermatology. The Company's products include AB PHYLLINE, ABZORB DUSTING POWDER, ACAMPROL, ACOSTIN 3 MIU, ACOSTIN FORTE and AB PHYLLINE SR 200. Its manufacturing units are situated in India, the United States and Brazil, among others. Its units produce generics, branded generics, specialty products, over-the-counter (OTC) products, anti-retroviral (ARVs) and APIs. They also produce intermediates in a range of dosage forms, including tablets, capsules, injectables, ointments, creams and liquids.

Industry

Biotechnology & Drugs

Contact Info

Acme Plaza

Andheri Kurla Road, Andheri East

400063

India

+91.22.43244324

http://www.sunpharma.com/

Executive Leadership

Israel Makov

Non-Executive Chairman of the Board

C. S. Muralidharan

Chief Financial Officer

Uday Baldota

Chief Executive Officer - Taro Pharmaceutical Industries Limited

Abhay Gandhi

Chief Executive Officer - North America

Kirti Ganorkar

Chief Executive Officer - India Business

Key Stats

1.94 mean rating - 34 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2018

264.9K

2019

290.7K

2020

328.4K

2021(E)

338.0K
EPS (INR)

2018

12.960

2019

16.060

2020

16.780

2021(E)

24.884
Price To Earnings (TTM)
60.85
Price To Sales (TTM)
4.42
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
36.36
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Sun Pharma latest to sell COVID-19 drug favipiravir in India

India's Sun Pharmaceutical Industries Ltd said on Tuesday it would soon begin selling its version of favipiravir, becoming the latest generic drugmaker to supply the antiviral to treat COVID-19 in the world's third worst-hit nation.

UPDATE 1-Sun Pharma's U.S. unit donates malaria drug in coronavirus fight

Sun Pharmaceutical Industries Ltd's U.S. subsidiary said on Friday it had donated 2.5 million hydroxychloroquine sulfate tablets as a potential treatment for the rapidly spreading coronavirus.

Sun Pharma's U.S. unit donates hydroxychloroquine sulfate tablets in fight against coronavirus

A subsidiary of India's Sun Pharmaceutical Industries Ltd said on Friday it had donated 2.5 million hydroxychloroquine sulfate tablets in the United States as a potential treatment for coronavirus.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up